Nasdaq 100 Stocks SEC Filings — May 18, 2026

18-05-2026

ImmunityBio entered an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the Tokyo strain of BCG, aiming to address the chronic BCG shortage in the U.S. The agreement follows a positive Phase III readout (SWOG S1602) demonstrating non-inferior efficacy of the Tokyo strain versus TICE BCG in BCG-naïve high-grade NMIBC, with a hazard ratio of 0.82 (95.8% CI 0.63–1.08) against a non-inferiority margin of 1.34. ImmunityBio plans to engage the FDA to pursue U.S. approval and serve as the sole BLA applicant, while continuing its Expanded Access Program for recombinant BCG through its partnership with Serum Institute of India.

• · The Tokyo strain of BCG has been used in Japan for almost 30 years for high-risk NMIBC.
• · SWOG S1602 enrolled 1,000 patients (984 eligible) between February 2017 and December 2020, randomized 1:1:1 to TICE BCG (n=330), intravesical Tokyo-172 BCG (n=327), or intradermal priming + intravesical Tokyo-172 BCG (n=327).
• · Progression-free survival was similar across all arms.
• · The BCG shortage in the U.S. has persisted for over a decade.
• · ANKTIVA is FDA-approved in combination with BCG for BCG-unresponsive NMIBC with CIS; the Tokyo strain is investigational in the U.S.
• · The partnership gives ImmunityBio a second potential BCG source (the first being Serum Institute's rBCG).

18-05-2026

Estrella Immunopharma reported a net loss of $2.29M for Q1 2026, an 8.9% increase from $2.10M in Q1 2025, driven largely by a 28.5% surge in G&A expenses. However, the company improved its stockholders' deficit from ($10.37M) to ($5.27M) through a $7.24M net registered direct offering and reduced total liabilities by $4.62M, primarily by paying down $4.13M in related party accrued liabilities. Cash increased 39% to $1.93M, but operating cash burn widened dramatically to $6.70M from $0.47M year-over-year, signaling heavy near-term cash consumption.

• · R&D expenses were approximately 61% of total operating expenses in Q1 2026, with $1.375M from related party (same as prior year).
• · G&A expenses increased 28.5% YoY to $891,789, partly due to stock-based compensation of $146,714 in Q1 2026 vs $159,095 in Q1 2025.
• · The company issued 4,063,290 shares of common stock, prefunded warrants, and common stock warrants in a registered direct offering, generating gross proceeds of $7,999,988 but incurring $758,882 in transaction costs.
• · Warrants outstanding surged from 2,214,993 to 10,178,928, with 8,594,935 new warrants granted at a weighted average exercise price of $1.23 (down from $11.50).
• · Aggregate intrinsic value of stock options fell from $2.682M to $0.882M, indicating a significant drop in the company's stock price.
• · Net cash used in operating activities was $6.70M, largely due to a $4.125M payment of related party accrued liabilities.
• · The company had no revenue and remains in the development stage with an accumulated deficit of $39.28M.

18-05-2026

Artificial Intelligence Technology Solutions Inc. (AITX) announced via an 8-K filed on May 18, 2026, that its subsidiary RAD is launching SCANNA, a product designed to unlock smarter security from existing cameras. The announcement was made through a press release attached as Exhibit 99.1. No financial details were provided in this filing.

• · The press release is attached as Exhibit 99.1 to the Form 8-K.
• · The filing was made under Item 8.01 (Other Events) and Item 9.01 (Exhibits).

18-05-2026

Faraday Future announced $25M in new convertible note financing, bringing total financing to $70M over two months (including $45M from April), sufficient to support Phase 1 of its EAI robotics strategy by end of 2026. The company raised its full-year shipment target to 1,500 units and declared a shift from liquidity-driven to capital-structure-driven financing. However, only $12.5M is immediately available to the operating account; the remainder is in controlled accounts subject to conditions, and the company continues to face significant risks including insufficient share capital and Nasdaq compliance requirements.

• · SEC investigation concluded with no penalties.
• · Founding team has fully returned to the company.
• · The $25M convertible notes are unregistered and subject to trading restrictions.
• · Of the $25M, $12.5M is directly in the operating account; the remaining $12.5M is in controlled accounts with conditions for release.
• · The full strategic plan (upgraded from Ten-Punch Combo to Five Key Transformations) will be unveiled in YT's Investor Weekly Report on Sunday.
• · Key application scenarios: education, security inspection, reception and guided tours, performance, and university research.
• · Company expects to move EAI Vehicle business away from high-cost short-term funding toward operating cash flow, industry partnerships, and long-term capital.

18-05-2026

Yimutian Inc. (YMT) filed an amendment (20-F/A) to its annual report on May 18, 2026, containing boilerplate updates to its memorandum and articles of association regarding share transfer procedures, board authority to issue preferred shares without shareholder vote, and the ability to register by continuation in another jurisdiction. The filing provides no financial data, operational metrics, or material business developments.

18-05-2026

Cottonwood Communities, Inc. disclosed the issuance of 257,866 shares of its Series 2025 Preferred Stock between April 22 and May 17, 2026, raising $2,541,000 in net proceeds after commissions and fees. The offering, launched December 9, 2024, has a maximum of $150,000,000 and remains ongoing. As of May 17, 2026, 11,314,733 shares of Series 2025 Preferred Stock were outstanding.

• · Offering launched December 9, 2024, with a maximum of $150,000,000 in shares.
• · Purchase price is $10.00 per share with discounts available to certain categories of purchasers.
• · The offering is conducted under Rule 506(b) of Regulation D, exempt from registration, and limited to accredited investors without general solicitation.
• · Selling commissions of $117,060 and aggregate placement fees of $78,077 were paid in connection with the share sales.

18-05-2026

BNY Mellon Strategic Municipal Bond Fund, Inc. (DSM) filed a DEFA14A (additional proxy materials) on May 18, 2026. The filing consists solely of an image attachment with no textual financial or operational data, providing no new material information for investors.

18-05-2026

BNY Mellon Strategic Municipals, Inc. filed a DEFA14A definitive additional proxy statement with the SEC on May 18, 2026. This filing supplements previously submitted proxy materials for shareholder consideration. No specific financial data or narrative content could be extracted from the provided filing text due to embedded image encoding.

18-05-2026

Genco Shipping & Trading Ltd filed an amendment to its tender offer response (SC 14D9/A) reporting strong Q1 2026 financial results compared to a loss in Q1 2025. Net income swung to $9.3 million from a net loss of $11.9 million, and adjusted EBITDA surged over 350% to $36.2 million. However, daily vessel operating expenses rose 3.2% year-over-year, and the company recorded impairment charges of $0.5 million. The filing also reiterates management's solicitation of proxies for the 2026 Annual Meeting using a WHITE proxy card, amid an ongoing tender offer.

• · Net interest expense increased to $3.8M in Q1 2026 from $2.2M in Q1 2025.
• · Depreciation and amortization rose to $21.0M from $17.7M year-over-year.
• · Net gain on sale of vessels of $2.1M and other operating expense of $3.8M were recorded in Q1 2026 (none in Q1 2025).
• · Realized loss on fuel hedges of $40k in Q1 2026 vs a gain of $8k in Q1 2025.
• · The company provides estimated TCE for Q2 2026 (not quantified in filing) based on fixtures to date and FFA curve.
• · The filing is an amendment to a Schedule 14D-9, indicating an active tender offer; the company recommends shareholders vote the WHITE proxy card.

18-05-2026

abrdn Palladium ETF Trust (PALL) executed a 5-for-1 forward stock split on May 18, 2026. Pre-split shares outstanding were 6,112,500 with a net asset value (NAV) of $128.69 per share; post-split shares increased to 30,562,500 with the NAV adjusted to $25.74 per share. The split does not change the total value of the trust, and the CUSIP number and ticker symbol (PALL) remain unchanged.

• · The forward split was announced in a press release issued on April 22, 2026.
• · The record date for the split was the close of markets on May 14, 2026.
• · The trust's CUSIP number and ticker symbol (PALL) were not affected by the split.

18-05-2026

Acadia Healthcare Company, Inc. disclosed on May 18, 2026 that a jury awarded $35 million in compensatory damages and $70 million in punitive damages (total $105 million) in an employment-related retaliatory termination lawsuit against its indirect subsidiary, Fashion Valley CTC. The company strongly disagrees with the verdict and intends to challenge it through post-trial motions and appeal. The outcome remains uncertain.

• · The lawsuit was filed by a former employee who was terminated in October 2023, alleging retaliatory termination.
• · The trial began in late April 2026 and the verdict was reached on May 12, 2026.
• · Acadia Healthcare Company, Inc. is not a party to the lawsuit; only its indirect subsidiary Fashion Valley CTC is the defendant.
• · Fashion Valley operates a comprehensive treatment center in San Diego County, California.
• · The company stated the award 'far exceeds any reasonable expectation based on precedent for comparable employment cases.'

18-05-2026

Madison Technologies Inc. reported no revenue for Q1 2026, with a net loss of $660,455, an improvement of 6.9% from $709,477 in Q1 2025. Operating expenses fell 26.8% to $86,353 and interest expense declined 3.0% to $574,102, while cash used in operations surged 117.7% to $197,432, fully funded by a loan from a principal shareholder. Total liabilities increased to $24.1 million and stockholders' deficiency worsened to ($24.0 million), with zero cash on hand.

• · No revenue reported for either quarter; zero cash on hand throughout.
• · Prepaid expenses decreased from $130,568 to $90,921 (down 30.3%).
• · Accounts payable and accrued liabilities increased from $3,898,315 to $3,979,715 (up 2.1%), while accrued interest rose $212,125 to $3,192,632.
• · Loan from principal shareholder increased $197,432 to $923,014, exactly matching the operating cash deficit.
• · Senior secured notes remained at $7,340,093 with no amortization in the period.
• · Weighted average shares outstanding increased by 75 million shares (4.7%) compared to the prior year period.
• · No income tax expense or interest paid in either quarter.

18-05-2026

Arkadios Wealth Advisors filed its quarterly 13F-HR for the period ending March 31, 2026, revealing a portfolio valued at approximately $6.13 billion. The largest equity positions include Amazon, Invesco QQQ Trust, and Vanguard Total Stock Market ETF. Notably, the firm held extensive put option positions on the QQQ ETF, suggesting a hedged or cautious outlook on large-cap tech.

• · The report contains significant put option positions on the Invesco QQQ Trust (QQQ), with numerous contracts totaling over 20,000 shares in notional value (estimated $11M+ in premiums based on reported values).
• · Largest single equity by market value is Amazon.com Inc at approximately $78.6M across multiple accounts and options.
• · The portfolio includes a notable allocation to fixed-income ETFs, such as SPDR Portfolio Aggregate Bond ETF ($4.15M) and SPDR Portfolio Intermediate Term Treasury ETF ($7.83M).
• · Holdings span REITs (Alexandria, CubeSmart, Camden), energy (Vanguard Energy ETF, Sempra), healthcare (Johnson & Johnson, Elevance Health, DexCom), and technology (Hewlett Packard Enterprise, Akamai, Seagate).
• · The filing includes shares attributed to both 'ARK Advisory' and firm-wide accounts, with some positions marked as SOLE ownership without a sub-advisor designation.

18-05-2026

CoStar Group's DEFA14A filing details significant governance enhancements and executive compensation redesign in response to stockholder feedback following a 2025 Say-on-Pay vote. The Board formed a Capital Allocation Committee (including two activist-nominated directors) that reviewed and recommended a $1.5B share repurchase program, a $300M reduction in Homes.com investment in 2026 with a path to break-even by exiting 2029, and a redesigned compensation plan emphasizing rigorous performance metrics. While the company has taken positive steps to align pay with performance and return capital, the changes were prompted by activist pressure and relatively low stockholder support for the prior compensation program, suggesting ongoing investor concerns.

• · The Capital Allocation Committee held 6 meetings between May 9, 2025 and December 16, 2025, reviewing the long-range financial plan for Homes.com including breakeven and NPV analysis, historical IRR analysis of businesses, and cash flow analysis for capital return.
• · The Board added three independent directors in 2025, two of whom were designated by activist stockholders D.E. Shaw and Third Point.
• · The Say-on-Pay engagement reached out to 100% of top 50 stockholders; 100% of those who requested a meeting with the Board Chair or Compensation Committee Chair received one, and 76% of those respondents actually had such participation.
• · The Compensation Committee eliminated the legacy 280G excise tax gross-up from the CEO's employment agreement, supplemented the clawback policy to include time-based RSUs, and increased CEO minimum stock ownership guidelines from 6x to 10x base salary.
• · New PSU design includes an rTSR target raised to the 55th percentile (from 50th), with payout capped at 100% if absolute TSR is negative, and symmetrical payout schedules for performance metrics.
• · The short-term incentive for NEOs (excluding CEO) shifted from a 50-65% weighting on objective financial metrics to 80% for 2026; individual performance was reduced from 35-50% to 20%.
• · Stock options and annual performance-based restricted stock were eliminated; LTI now consists solely of PSUs and time-based RSUs.
• · The CEO's LTI mix moved from 40% PSUs / 45% RSUs / 15% options (2025) to 80% PSUs / 20% RSUs (2026).

18-05-2026

MetaVia Inc. announced on May 18, 2026 that three late-breaking abstracts highlighting its cardiometabolic assets DA-1726 (a dual oxyntomodulin analog targeting GLP-1 and glucagon receptors for obesity) and vanoglipel (DA-1241, a GPR119 agonist) have been accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions to be held June 5-8, 2026 in New Orleans. This is a positive clinical development milestone but no financial data or period-over period comparisons were provided

• · Three late-breaking abstracts were accepted
• · Conference: ADA 2026 Scientific Sessions, June Sessions, June 5-8, 2006 at Ernest N. Morial Convention Center in New Orleans, Louisiana
• · DA-1726 is a novel dual oxyntomodulin analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for obesity
• · Vanoglipel (DA-1241) is a novel G-protein-coupled receptor 119 (GPR119) agonist

18-05-2026